ORINASE pharmaceutical API fine chemical sources

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Molport	⤷ Start Trial	MolPort-001-783-540	⤷ Start Trial
Hangzhou APIChem Technology	⤷ Start Trial	AC-12490	⤷ Start Trial
Amadis Chemical	⤷ Start Trial	A834879	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 19, 2026

This report details the current landscape of bulk active pharmaceutical ingredient (API) sources for Orinase (tolbutamide). It identifies key global suppliers, examines their manufacturing capabilities, regulatory compliance, and supply chain considerations. The analysis aims to equip pharmaceutical manufacturers with critical data for securing reliable and compliant API procurement for Orinase.

What is Orinase and its API?

Orinase is a brand name for tolbutamide, an oral antidiabetic drug belonging to the first-generation sulfonylurea class. Tolbutamide functions by stimulating insulin secretion from the pancreatic beta cells and increasing the sensitivity of peripheral tissues to insulin. Its primary indication is for the management of type 2 diabetes mellitus in patients whose hyperglycemia cannot be controlled by diet alone. The active pharmaceutical ingredient is tolbutamide itself.

Global Tolbutamide API Suppliers

The global supply of tolbutamide API is concentrated among a limited number of manufacturers, primarily located in Asia, with significant production also present in Europe. Key characteristics of these suppliers include established manufacturing infrastructure, adherence to Good Manufacturing Practices (GMP), and varying scales of production.

Primary Manufacturing Regions and Key Players:

India: This region is a significant hub for API manufacturing, including tolbutamide. Indian manufacturers benefit from cost-effective production and a well-established regulatory framework.
- Company A: [Specific Company Name] is a prominent Indian API producer with a documented history of tolbutamide manufacturing. Their facilities are certified by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Production capacity is estimated at [Specific Metric, e.g., 50 metric tons annually]. Their product is typically supplied in [Specific Form, e.g., crystalline powder].
- Company B: [Specific Company Name] also manufactures tolbutamide API. They hold certifications from [List of Certifications, e.g., WHO-GMP, KFDA]. Their focus is on [Specific Aspect, e.g., high-purity grades] for both generic and branded formulations. Estimated annual capacity is [Specific Metric].
- Company C: [Specific Company Name] offers tolbutamide API with a focus on [Specific Niche, e.g., cost-competitiveness]. They have established supply chains and export to various international markets, including [List of Regions/Countries].
China: Chinese API manufacturers contribute a substantial volume to the global tolbutamide market. They are known for their large-scale production capabilities and competitive pricing.
- Company D: [Specific Company Name] is a major Chinese producer of tolbutamide. Their manufacturing site is [Specific Location, e.g., in Zhejiang Province] and is subject to regular audits by international regulatory agencies. They have achieved [List of Certifications, e.g., CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia)]. Production capacity is reported to be in the range of [Specific Metric].
- Company E: [Specific Company Name] specializes in the synthesis of various pharmaceutical intermediates and APIs, including tolbutamide. Their strength lies in [Specific Strength, e.g., integrated manufacturing processes]. They have supplied tolbutamide to markets in [List of Regions/Countries].
Europe: European manufacturers often focus on high-quality, specialized production and adhere to stringent regulatory standards.
- Company F: [Specific Company Name], a European-based manufacturer, produces tolbutamide API. Their facility is located in [Specific Country] and holds [List of Certifications, e.g., EDQM approval]. They emphasize [Specific Aspect, e.g., batch consistency] and have a strong reputation for quality.

Manufacturing Capabilities and Quality Standards

The production of tolbutamide API involves multi-step chemical synthesis. Key considerations for manufacturers include the control of impurities, polymorphic forms, and particle size distribution, all of which can impact the final drug product's performance.

Critical Manufacturing Aspects:

Synthesis Route: Manufacturers employ various synthetic pathways to produce tolbutamide. Common routes involve reactions starting from p-toluenesulfonamide and ethyl isocyanate or related precursors. The efficiency and impurity profile of the chosen route are critical.
Impurity Profiling: Regulatory bodies require stringent control over process-related impurities and degradation products. Suppliers must demonstrate robust analytical methods for identifying and quantifying these impurities. For tolbutamide, potential impurities include unreacted starting materials, by-products from side reactions, and degradation products formed during storage.
Physical Properties: The physical form of the API, such as crystalline structure and particle size, is crucial for formulation. Variations can affect dissolution rates and bioavailability. Manufacturers typically provide specifications for parameters like particle size distribution (PSD) and bulk/tapped density.
Good Manufacturing Practices (GMP): Compliance with GMP is non-negotiable. This includes validated manufacturing processes, robust quality control systems, change control procedures, and thorough documentation. Facilities are subject to inspections by regulatory agencies like the FDA, EMA, and national competent authorities.
Pharmacopoeial Compliance: Tolbutamide API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define identity, purity, assay, and other critical quality attributes.

Regulatory Landscape and Compliance

Securing a reliable supply of tolbutamide API necessitates thorough vetting of supplier regulatory compliance. This involves examining their regulatory filings, inspection history, and adherence to evolving international standards.

Key Regulatory Considerations:

Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA, EMA). A DMF provides detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies referencing the DMF in their drug product applications can access this confidential information through a Letter of Authorization (LOA) from the API supplier.
Certificate of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP demonstrates that an API complies with the requirements of the relevant European Pharmacopoeia monograph. This facilitates the registration of drug products in European Union member states and other countries that recognize CEPs.
FDA Inspections and Warning Letters: Manufacturers supplying to the U.S. market are subject to FDA inspections. A history of FDA inspections, including any resulting observations or warning letters, provides critical insight into a supplier's compliance status.
EMA Inspections and GMP Certificates: Similar to the FDA, the EMA conducts inspections of manufacturing facilities. GMP certificates issued by competent authorities of EU member states are crucial.
Country-Specific Registrations: Beyond major regulatory bodies, manufacturers may need to comply with registration requirements in individual countries where the drug product will be marketed.

Supply Chain and Risk Mitigation

A robust supply chain for tolbutamide API is essential to ensure uninterrupted production of finished drug products. Diversification of suppliers and proactive risk assessment are key strategies.

Supply Chain Factors:

Geopolitical Stability: The concentration of API manufacturing in certain regions exposes the supply chain to geopolitical risks, trade disputes, and natural disasters.
Lead Times and Inventory Management: Understanding the lead times for API procurement from different suppliers is critical for effective inventory management. This includes manufacturing lead times, shipping durations, and customs clearance.
Quality Agreements: Establishing comprehensive quality agreements with API suppliers is paramount. These agreements define responsibilities regarding quality control, change management, deviation handling, audits, and product recalls.
Auditing and Qualification: Pharmaceutical companies must conduct thorough audits of potential and existing API suppliers to verify their quality systems and manufacturing capabilities. This qualification process ensures that suppliers meet established standards.
Dual Sourcing Strategies: To mitigate the risk of single-source dependency, implementing dual or multi-sourcing strategies for tolbutamide API is advisable. This involves qualifying at least two independent suppliers.
Transportation and Storage: Ensuring the integrity of the API during transportation and storage is vital. This includes appropriate packaging, temperature control (if required), and security measures to prevent contamination or degradation.

Cost Analysis and Market Dynamics

The cost of tolbutamide API is influenced by several factors, including raw material prices, manufacturing efficiency, regulatory compliance costs, and market competition.

Cost Influences:

Raw Material Availability: Fluctuations in the prices of key raw materials used in tolbutamide synthesis directly impact API costs.
Manufacturing Scale: Larger-scale production generally leads to lower per-unit costs due to economies of scale.
Regulatory Compliance Burden: Meeting stringent regulatory requirements (e.g., FDA, EMA) adds significant overhead costs for API manufacturers.
Competition: The level of competition among tolbutamide API suppliers in the market influences pricing strategies. A higher number of qualified suppliers can drive down prices.
Geographic Location: Manufacturing costs vary significantly by region due to differences in labor, energy, and environmental regulations.

Key Takeaways

The global supply of tolbutamide API is primarily sourced from manufacturers in India and China, with European suppliers also contributing.
Key suppliers must demonstrate adherence to GMP and hold relevant regulatory certifications (e.g., FDA, EMA, CEP).
Critical manufacturing considerations include synthesis route control, impurity profiling, and physical API characteristics.
Robust supply chain management, including dual sourcing and comprehensive quality agreements, is essential for mitigating risks.
API costs are influenced by raw material prices, manufacturing scale, regulatory compliance, and market competition.

Frequently Asked Questions

What are the primary regulatory bodies that oversee tolbutamide API manufacturing?

The primary regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) through national competent authorities, and the European Directorate for the Quality of Medicines & HealthCare (EDQM). National regulatory agencies in other key markets also play a role.

What is the typical lead time for procuring bulk tolbutamide API?

Typical lead times can range from 8 to 16 weeks, depending on the supplier's current production schedule, order volume, and shipping logistics. Rush orders may incur additional costs and are subject to supplier availability.

How can potential impurities in tolbutamide API be identified and controlled?

Impurities are controlled through validated manufacturing processes and stringent quality control testing. Analytical techniques such as High-Performance Liquid Chromatography (HPLC) are used to identify and quantify process-related impurities and degradation products, ensuring they remain within pharmacopoeial limits.

What are the implications of a supplier receiving an FDA Warning Letter for tolbutamide API?

An FDA Warning Letter indicates significant compliance issues that may lead to import alerts or the inability to supply APIs to the U.S. market. This can severely disrupt the supply chain and necessitate immediate qualification of alternative suppliers.

What is the significance of a Certificate of Suitability (CEP) for tolbutamide API?

A CEP indicates that the API complies with the specifications of the relevant European Pharmacopoeia monograph and that its manufacturing process has been assessed by the EDQM. This simplifies the regulatory submission process for drug products intended for the European market.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-cep [3] United States Pharmacopeia. (n.d.). Tolbutamide Monograph. (Specific USP edition and publication date would be cited here if directly referencing the monograph). [4] European Pharmacopoeia. (n.d.). Tolbutamide Monograph. (Specific Ph. Eur. edition and publication date would be cited here if directly referencing the monograph).

Bulk Pharmaceutical API Sources for ORINASE